Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma

被引:2
作者
Kim, Joon Mo [1 ]
Kim, Tae-Woo [2 ]
Park, Sang-Woo [3 ,4 ]
Park, Hae-Young Lopilly [5 ]
Hwang, Young Hoon [6 ]
Jeoung, Jin Wook [7 ]
Kim, Chan Yun [8 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Ophthalmol, Seongnam, South Korea
[3] Chonnam Natl Univ, Med Sch & Hosp, Dept Ophthalmol, Gwangju, South Korea
[4] Chonnam Natl Univ, Med Sch & Hosp, Res Inst Med Sci, Gwangju, South Korea
[5] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea
[6] Chungnam Natl Univ Hosp, Dept Ophthalmol, Daejeon, South Korea
[7] Seoul Natl Univ, Dept Ophthalmol, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea
[8] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol,Severance Hosp, Seoul, South Korea
关键词
Open-angle glaucoma; intraocular pressure; brimonidine; timolol fixed combination; preservative-free; normal-tension glaucoma;
D O I
10.1080/08820538.2021.1885722
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the therapeutic efficacy and safety of newly developed preservative-free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solutions and a preservative-containing (PC) BTFC ophthalmic solution in patients with open-angle glaucoma. Methods: This study was conducted as a multicenter, randomized, open-label, parallel-group clinical trial to evaluate the efficacy and safety of PF BTFC as compared with PC BTFC in adult patients (aged >= 19 years) with open-angle glaucoma (OAG) and ocular hypertension (OHT). A total of the 106 patients were enrolled, with 53 patients each randomized to the two treatment groups and included in the analysis of the safety set (SS). After a washout period, patients with an IOP below 35 mmHg at 9 a.m. were enrolled. After a full ophthalmic and glaucoma examination, a total of 106 OAG and OHT patients were randomized to the PF group or PC group. All subjects were examined 4 and 12 weeks after first administration. At each follow-up visit, IOP was measured at 9 a.m. and 11 a.m. and the efficacy, safety, and compliance were evaluated. Throughout the study, all adverse events were recorded and monitored by the investigators. Results The mean IOP changes from baseline to 12 weeks at 11:00 a.m. were -3.45 +/- 2.53 mmHg in the PF group and -3.65 +/- 2.76 mmHg in the PC group (p < .0001 for both). The difference in mean IOP change between the two groups was 0.20 +/- 2.65 mmHg, which was not significantly different. The proportion of patients with IOP reductions of >= 15% and >= 20% and IOP at all-time points in the PF group were not significantly different when compared with in the PC group. There were no specific differences between the two groups regarding the incidence of adverse events. Conclusions PF BTFC ophthalmic solution shows a similar efficacy and safety profile to that of PC BTFC.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 33 条
[11]   Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial [J].
DuBiner, Harvey B. ;
Hubatsch, Douglas A. .
BMC OPHTHALMOLOGY, 2014, 14
[12]   Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial [J].
Goldberg, Ivan ;
Pina, Rafael Gil ;
Lanzagorta-Aresti, Aitor ;
Schiffman, Rhett M. ;
Liu, Charlie ;
Bejanian, Marina .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (07) :926-931
[13]  
HEIJL A, 2002, ARCH OPHTHALMOL-CHIC, V120
[14]  
KASS MA., 2002, Arch Ophthalmol, V120
[15]  
Kim Han Ul, 2019, Korean J Ophthalmol, V33, P379, DOI 10.3341/kjo.2018.0094
[16]  
Kim Jee Hyun, 2015, Korean J Ophthalmol, V29, P270, DOI 10.3341/kjo.2015.29.4.270
[17]   Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients [J].
Kim, Joon Mo ;
Kim, Tae-Woo ;
Kim, Chan Yun ;
Kim, Hwang Ki ;
Park, Ki Ho .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2016, 60 (01) :20-26
[18]  
Kwon Junki, 2015, Korean J Ophthalmol, V29, P344, DOI 10.3341/kjo.2015.29.5.344
[19]   Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues [J].
Lee, Sang Yeop ;
Lee, Kwanghyun ;
Park, Chan Keum ;
Kim, Sangah ;
Bae, Hyoung Won ;
Seong, Gong Je ;
Kim, Chan Yun .
PLOS ONE, 2019, 14 (06)
[20]   Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost [J].
Martinez-de-la-Casa, Jose M. ;
Perez-Bartolome, Francisco ;
Urcelay, Elena ;
Santiago, Jose L. ;
Moreno-Montanes, Javier ;
Arriola-Villalobos, Pedro ;
Benitez-del-Castillo, Jose M. ;
Garcia-Feijoo, Julian .
OCULAR SURFACE, 2017, 15 (04) :723-729